Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: BUY (auto-tracking)
-0.57% $3.48
America/New_York / 26 apr 2024 @ 14:07
FUNDAMENTALS | |
---|---|
MarketCap: | 69.36 mill |
EPS: | -0.220 |
P/E: | -15.82 |
Earnings Date: | May 20, 2024 |
SharesOutstanding: | 19.93 mill |
Avg Daily Volume: | 0.170 mill |
RATING 2024-04-26 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -15.82 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.33x |
Company: PE -15.82 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.97 - 3.99 ( +/- 14.66%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Rosenwald Lindsay A Md | Buy | 10 000 | Common Stock, $0.0001 par value |
2024-03-22 | Maraoui Claude | Buy | 10 000 | Common Stock, $0.0001 par value |
2024-03-22 | Smith Justin Adam | Buy | 30 000 | Common Stock, $0.0001 par value |
2024-03-22 | Rosenwald Lindsay A Md | Buy | 20 000 | Common Stock, $0.0001 par value |
2024-02-22 | Benesch Joseph | Sell | 2 450 | Common Stock, $0.0001 par value |
INSIDER POWER |
---|
75.81 |
Last 94 transactions |
Buy: 1 155 250 | Sell: 1 927 470 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.48 (-0.57% ) |
Volume | 0.0323 mill |
Avg. Vol. | 0.170 mill |
% of Avg. Vol | 19.00 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $4.76 | N/A | Active |
---|
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.